Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
НЦПЗ РАМН
Список исп. литературыСкрыть список 1. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with ExelonTM (ENA-173) in Alzheimer\'s disease: an overview. J Drug Dev Clin Pract 1996; 8: 109–16. 2. Anand R, Gharabawi С. Clinical development of Exelon (ENA-713): the ADENA programme. J Drug Dev Clin Pract 1996; 8: 117–22. 3. Anand R. Clinical expert report: Exelon. Alzheimer\'s disease. Basle, Switzerland: Novartis Pharma. AG 1997. 4. Auriacombe S, Pere J-J, Loria-Kanza Y, Vellas B. Efficacy and Safety of Rivastigmine in Patients with Alzheimer\'s Disease who Failed to Benefit from Treatment with Donepezil. Current Medical Research and Opinion 2002; 18 (3): 129–38. 5. Bullock R, Moulias R, Steinwachs K-C et al. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer\'s disease: a European open-label multicentre study. Int Psychogeriatrics 2001; 13 (Suppl. 2). Abstr. 248. 6. Corey-Bloom J, Anand R, Vcach J. for the ENA-713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer\'s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65. 7. Coyle JT, Price DL, DeLong MR. Alzheimer\'s disease: a disorder of cortical chollnergic innervation. Science 1985; 219: 1184–90. 8. Culter NR, Polinsky RJ, Sramek JJ et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA713 in Alzheimer’s disease. Acta Neurol Scand 1998; 97: 244–50. 9. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2000; 8: 134–40. 10. Davies P, Maloney A. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976; 1403. 11. Doraiswamy PM. Current cholinergic therapy for symptoms of Alzheimer’s disease. Primary Psychiatry 1996; 3 (11): 3–11. 12. Drachman D, Leavitt J. Human memory and the cholinergic system: relationship to aging? Arch Neurol 1974; 30: 113–21. 13. Etemad B. Behavioural and cognitive benefits of rivastigmine in nursing home patients with Alzheimer\'s disease and related dementias: a 26-week follow up. Int Psychogeriatr 2001; 13 (Suppl. 2): 241. 14. Farlow M, Anand R. Patterns of cholineslcrase inhibition in normal controls and Alzheimer\'s disease patients: Correlation of cognitive improvement with the type of esterase inhibition. Springfield Symposium on Advances in Alzheimer Therapy, April 2000. 15. Giaccobini E. Cholinesterase inhibitors: from preclinical studies to clinical efficacy in Alzheimer disease. In: Quinn D et al (eds): Enzymes of the Cholinesterase Family. NY: Plenum Press 1995; 463–9. 16. Grossberg G, Irwin P, Spiegel R et al. Rivastigmine in Alzheimer\'s disease: efficacy over two years compared with historical controls. Poster presented at 10th Congress of the International Psychogcriatric Association (IPA). Nice, France 9–14 Sept., 2001. 17. Kalaria RN. The role of cerebral ischemia in Alzheimer\'s disease. Neurobiol Aging 2000; 57: 1295–300. 18. Kumar V, Anand R, Messina J et al. An efficacy and safety analysis of Exelon in Alzheimer\'s disease with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159–69. 19. McKeith I, Del Ser T, Spano F et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–6. 20. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer`s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer`s disease. Neurology 1984; 146: 939–44. 21. Mesulam M, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994; 36: 722–7. 22. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine is safe and effective for at least 22 months in patients with subcortical vascular dementia. Second International Congress on Vascular Dementia. Salzburg, Austria, Jan 25 2002. Abstr. 37. 23. Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther 1998; 20 (4): 634–47. 24. Potkin SG, Anand R, Hartman R, Veach J. Impact of Alzhcimer\'s disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002. 25. Rsler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer\'s disease: international randomised controlled trial. BMJ 1999. 26. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer\'s disease. Int J Geriatr Psychophannacol 1998; 26–34. 27. Shea C, McKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10: 229–38. 28. Sunderland T, Silver MA. Neuroleptics and the treatment of dementia. Int J Geriatr Psychiatry 1988; 3: 79–88. 29. Wilson AL, Langley LK, Monley J et al. Nicotine patches in Alzheimer’s disease: pilot study on learning, memory and safety. Pharmacol Biochem Behav 1995; 51 (2–3): 509–14. 30. Букатина Е.Е. Фармакологическая терапия когнитивных нарушений при болезни Альцгеймера: достижения и перспективы. Соц. и клин. психиатр. 1997. Т. 7. С. 136–51. 31. Гаврилова С.И. Фармакотерапия болезни Альцгеймера. М., 2007. 32. Гаврилова С.И. Фармакотерапия болезни Альцгеймера: миф или реальность? В кн.: Болезнь Альцгеймера и старение: от нейробиологии к терапии. Матер. II Росс. конф. Под ред. Гавриловой С.И. М., 1999. С. 25–33. 33. Колыхалов И.В., Селезнева Н.Д., Калын Я.Б. и др. Клиническая эффективность экселона при болезни Альцгеймера. В кн.: Болезнь Альцгеймера и старение: от нейробиологии к терапии. Матер. II Росс. конф. Под ред. С.И.Гавриловой. М., 1999. С. 90–7.